Lightlake appoints VP, medical affairs
This article was originally published in Scrip
Lightlake Therapeutics, a biopharmaceutical company developing addiction treatments using opioid antagonists, has named Arvind Agrawal executive vice-president of medical affairs. During his career, Mr Agrawal has overseen, managed, and delivered global Phase I-IV clinical studies and has experience in the therapeutic areas of addiction, psychiatry, CNS, respiratory, cardiovascular, and diabetes. Prior to joining Lightlake, he was head of medical affairs for new products at Mundipharma.
You may also be interested in...
The Scrip 100 universe gathers FY 2019 financial performance data and compares the activities of the Top 100 biopharma businesses, ranked by pharma sales. Here In Vivo breaks out the Top 10 in the league table. Which big pharma holds the top spot this year?
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.